OR WAIT null SECS
January 02, 2008
As FDA implements new drug-safety policies, manufacturers will focus on quality and pricing.
December 02, 2007
To keep up with applications, FDA promotes new testing and administrative methods.
November 02, 2007
New FDA act reshapes drug development and marketing to restore public trust in pharmaceutical regulation.
October 02, 2007
Expanded access to drugs for seniors has increased demand and focused attention on costs.
September 02, 2007
User-fee legislation will require more testing and data disclosure to prevent unsafe drug use.
August 02, 2007
FDA's long-awaited GMPs for supplements appear as food and drug safety concerns override lingering opposition.
June 02, 2007
Product characterization and production challenges are key issues in developing a pathway for biosimilar therapies.
May 02, 2007
Fewer field offices and inspectors will increase reliance on manufacturers to ensure product and process quality.
April 02, 2007
FDA is buried in postapproval manufacturing submissions and seeks to reduce the scope of changes that require agency scrutiny.
March 02, 2007
FDA's new safety program, Critical Path Initiative, and user-fee proposal seek to reinvigorate pharmaceutical R&D.